GlassScriptPhysician profile
Clarence G White
NPI 1043330004
$1,547.16
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $805 · 2023: $541 · 2024: $37.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.99 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $465.38 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $205.93 | 2021-2022 | |
| Alkermes, INC. | $199.07 | 2022-2023 | Aristada, Lybalvi |
| Corium, LLC | $162.46 | 2022 | |
| Neurocrine Biosciences, INC. | $105.07 | 2022-2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $97.25 | 2022-2023 | Quviviq |
| Indivior INC. | $50.95 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2023 | |
| Harmony Biosciences LLC | $36.37 | 2023 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $25.66 | 2022 | |
| Merck Sharp & Dohme LLC | $23.92 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.08 | 2021 | |
| Azurity Pharmaceuticals, INC. | $20.14 | 2023 | Horizant |
| Eisai INC. | $18.42 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $17.71 | 2023 | Xelstrym |
| Neos Therapeutics, LP | $14.12 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarence White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.